目的 研究阿托伐他汀聯(lián)合曲美他嗪對(duì)冠心病患者心功能和超敏C-反應(yīng)蛋白（hs-CRP）、白介素-6（IL-6）、血漿纖維蛋白（Fib）的影響。方法 選擇2014年1月-2016年1月在咸陽市第一人民醫(yī)院進(jìn)行診治的冠心病患者120例，隨機(jī)分為兩組。觀察組采用阿托伐他汀聯(lián)合曲美他嗪治療，對(duì)照組采用曲美他嗪治療，觀察和比較兩組的療效、左心室射血分?jǐn)?shù)、左心室舒張末期內(nèi)徑、左心室后壁厚度及血清hs-CRP、IL-6、Fib水平。結(jié)果 觀察組的治療有效率為91.67%（55/60），明顯高于對(duì)照組的76.67%（46/60）（P<0.05）；兩組的左心室射血分?jǐn)?shù)、左心室舒張末期內(nèi)徑、左心室后壁厚度均較治療前明顯改善（P<0.05），且觀察組的改善程度明顯優(yōu)于對(duì)照組（P<0.05）；兩組的血清hs-CRP、IL-6、Fib水平均明顯降低（P<0.05），且觀察組降低的更為明顯（P<0.05）；兩組不良反應(yīng)發(fā)生率相比無明顯差異。結(jié)論 阿托伐他汀聯(lián)合曲美他嗪治療冠心病患者療效確切，能改善心功能，明顯降低hs-CRP、IL-6、Fib水平，值得臨床應(yīng)用推廣。

Objective To investigate the effect of trimetazidine combined with atorvastatin on cardiac function and the level of hs-CRP, IL-6, and Fib in patients with coronary heart disease. Methods Patients (120 cases) with coronary heart disease in the first people's Hospital of Xianyang City from January 2014 to January 2016 were selected and randomly divided into two groups. The observation group was treated with trimetazidine combined with atorvastatin, the control group was treated with trimetazidine, the curative effect, left ventricular ejection fraction, left ventricular diastolic end systolic diameter, left ventricular posterior wall thickness and serum hs-CRP, IL-6, and Fib levels were compared. Results The effective rate of observation group was 91.67% (55/60), significantly higher than the control group 76.67% (46/60) (P<0.05); The left ventricular ejection fraction, left ventricular end-diastolic diameter, and left ventricular posterior wall thickness of two groups were significantly improved (P<0.05), and the improvement of the observation group was significantly better than that of control group (P<0.05); The serum levels of hs-CRP, IL-6, and Fib were significantly lower (P<0.05), and the observation group was more obvious (P<0.05); The incidence of adverse reactions of two groups had no significant difference. Conclusion Trimetazidine combined with atorvastatin have high curative effect on coronary heart disease, and can improve cardiac function, significantly reduce the levels of hs-CRP, IL-6, and Fib, worth clinical promotion.